Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...

Pfizer (PFE) closed the most recent trading day at $26.21, moving -0.38% from the previous trading session. This move lagged the S&P 500's daily gain of 1.08%. Meanwhile, the Dow gained 0.92%, and the ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

And when a stock's fair value is higher than ... Therefore, knowing a company's potential revenue growth is crucial. In the case of Pfizer, the consensus sales estimate of $13.99 billion for ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Those who own this Zacks Rank #3 (Hold) stock may stay invested to see how Pfizer’s new growth drivers perform. Investors with a long-term horizon may consider buying Pfizer’s stock at the ...